Comparison of antibodies to HBME‐1 and calretinin for the detection of mesothelial cells in effusion cytology

The distinction of mesothelial cells in cytologic samples is often a diagnostic challenge. This is particularly true in potentially malignant effusions in which reactive mesothelial cells may simulate adenocarcinoma (ACA) cells, and in the differentiation of ACA vs. mesothelioma. We sought to determine the superior antibody for the positive identification of mesothelial cells in these circumstances.

[1]  A. Simsir,et al.  Calretinin immunostaining in benign and malignant pleural effusions , 2001, Diagnostic cytopathology.

[2]  J. Krane,et al.  Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations , 2000, Cancer.

[3]  R. Attanoos,et al.  Anti‐mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms , 2000, Histopathology.

[4]  A. Hjerpe,et al.  An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. , 2000, American journal of clinical pathology.

[5]  L. Chiriboga,et al.  Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions , 2000, Cancer.

[6]  Edwards,et al.  HBME‐1, MOC‐31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma , 2000, Histopathology.

[7]  Y. Inayama,et al.  Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma , 2000, Cancer.

[8]  A. Nicholson,et al.  Value of the Mesothelium-Associated Antibodies Thrombomodulin, Cytokeratin 5/6, Calretinin, and CD44H in Distinguishing Epithelioid Pleural Mesothelioma from Adenocarcinoma Metastatic to the Pleura , 2000, Modern Pathology.

[9]  P. Fetsch,et al.  Utility of the antibodies CA 19‐9, HBME‐1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology , 1998, Cancer.

[10]  Leers,et al.  E‐cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma , 1998, Histopathology.

[11]  B. Hemmerlein,et al.  The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology. , 1998, Pathology, research and practice.

[12]  G. Viale,et al.  Calretinin: a novel immunocytochemical marker for mesothelioma. , 1996, The American journal of surgical pathology.

[13]  P. Vogt,et al.  The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. , 1996, Pathology, research and practice.

[14]  D. Allred,et al.  Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. , 1993, Human pathology.

[15]  W. Mccarthy,et al.  Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[16]  J. Rogers,et al.  Calretinin and other CaBPs in the nervous system. , 1990, Advances in experimental medicine and biology.

[17]  N. Ordóñez.  The Immunohistochemical Diagnosis of Mesothelioma: Differentiation of Mesothelioma and Lung Adenocarcinoma , 1989, The American journal of surgical pathology.